Table 1.

Quiescence-Associated Genes with High Functional and Prognostic Significance.

Name	HUGO Symbol	Entrez ID	Ensembl ID	Log2 Fold-Change a	DE q-Value b	MSigDB Hallmark Gene Set Leading Edges c	Centrality Score d	Centrality Designation e	Correlation with Late Recurrence f	Metastasis Associated g	Quiescence or Dormancy Associated h
C-C motif chemokine ligand 5	CCL5	6352	ENSG00000271503	2.75622625	6.40 × 10−7	5	1.726356886	Low	CB572 + CB482	+	+
cellular communication network factor 3	CCN3	4856	ENSG00000136999	1.159158799	0.003129394	0	2.369572457	High	CB572 + CB482	+
cadherin 11	CDH11	1009	ENSG00000140937	0.924409835	0.001008869	2	0.017134571	Low	CB572 + CB482	+	+
collagen type XVII alpha 1 chain	COL17A1	1308	ENSG00000065618	1.159975436	0.002670111	0	2.021417131	High	CB572 + CB482	+
formyl peptide receptor 3	FPR3	2359	ENSG00000187474	2.954316158	3.43 × 10−8	0	2.487201841	High	CB572	+
3-hydroxy-3-methylglutaryl-CoA synthase 2	HMGCS2	3158	ENSG00000134240	1.36731073	0.000805151	2	0.004347429	Low	CB572 + CB482	+
insulin like growth factor binding protein 5	IGFBP5	3488	ENSG00000115461	1.115110029	0.00391699	0	2.801887967	High	CB572 + CB482	+
kallikrein related peptidase 8	KLK8	11202	ENSG00000129455	1.33535789	7.97 × 10−5	3	1.277111171	Low	CB482	+
maltase-glucoamylase	MGAM	8972	ENSG00000257335	1.391777411	0.042802637	0	2.039476442	High	CB572 + CB482	+
mucin 5AC, oligomeric mucus/gel-forming	MUC5AC	4586	ENSG00000215182	1.422900799	0.000379937	0	2.021250734	High	CB572	+	+
2’-5’-oligoadenylate synthetase like	OASL	8638	ENSG00000135114	1.151350653	0.023043447	2	2.819995388	High	CB572 + CB482
plasminogen activator, tissue type	PLAT	5327	ENSG00000104368	1.053223792	0.031200647	4	2.391649253	High	CB572	+
prostaglandin F receptor	PTGFR	5737	ENSG00000122420	1.228190238	0.004757316	2	2.315990672	High	CB482	+
prostaglandin-endoperoxide synthase 2	PTGS2	5743	ENSG00000073756	1.429349462	0.022239393	3	2.233337779	High	CB482	+
protein tyrosine phosphatase receptor type H	PTPRH	5794	ENSG00000080031	1.065756445	0.001072713	0	2.487144917	High	CB572	+
protein tyrosine phosphatase receptor type N2	PTPRN2	5799	ENSG00000155093	1.878824513	2.86 × 10−5	0	2.607454659	High	CB572	+
radical S-adenosyl methionine domain containing 2	RSAD2	91543	ENSG00000134321	1.765109846	8.21 × 10−7	3	0.021323383	Low	CB572 + CB482	+
serpin family A member 1	SERPINA1	5265	ENSG00000197249	1.203836437	7.93 × 10−6	3	2.928302569	High	CB482	+
serpin family A member 3	SERPINA3	12	ENSG00000196136	1.255309782	0.00051306	2	0.008651795	Low	CB572	+
serpin family E member 1	SERPINE1	5054	ENSG00000106366	1.423828199	0.013356874	8	2.933522416	High	CB572	+
TNF receptor superfamily member 10c	TNFRSF10C	8794	ENSG00000173535	1.136170418	0.013356874	0	2.021292344	High	CB482	+
von Willebrand factor A domain containing 5A	VWA5A	4013	ENSG00000110002	1.412217075	0.001530294	2	0.00434743	Low	CB482

^a Log₂-transformed fold change in mean normalised gene transcript counts as determined by RNA-Seq (proliferating Vybrant^® DiD- versus quiescent Vybrant^® DiD+ sub-populations), ^b False discovery rate adjusted p-value of differential expression according to comparison of mean normalised gene transcript counts, ^c Number of times the corresponding gene was found in the leading edge gene set driving the statistically significant enrichment of one of the MSigDB Hallmark gene sets analysed in GSEA, ^d Centrality score calculated as the log₁₀-transformed weighted sum of total degree, betweenness, eigenvalue, and closeness centrality metrics combined by multidimensional scaling, ^e Designation as having a “high” or “low” centrality score metric relative to the 75th percentile cut-off value (centrality score ≥ 2), ^f Indication of which clinical data set(s) in which the corresponding gene was found to have a statistically significant association with late metastatic recurrence (≥5 years after primary tumour diagnosis) by Cox regression analysis, ^g Association with metastasis according to automated mining of PubMed^® using the search “gene[Title/Abstract] AND metasta*[Title/Abstract]”, ^h Association with dormancy or quiescence in cancer according to automated mining of PubMed^® combining the results of searches “gene[Title/Abstract] AND quiescen*[Title/Abstract] AND cancer[Title/Abstract]” or “gene[Title/Abstract] AND dorman*[Title/Abstract] AND cancer[Title/Abstract]”.